What is a "food-derived bioactive technology" and a "functional food"?
It is becoming increasingly accepted by the scientific community that there are links between specific food groups and their capacity to help reduce the risk of certain diseases. For example, some compounds specifically found in broccoli have been shown to reduce the risk of some cancers. Consuming the actual food may be insufficient to maximise the health benefit due to a number of factors including: the quantity of the food that would need to be consumed; the frequency with which it would need to be consumed; and the way in which the food is prepared prior to consumption.

These health-promoting compounds can be extracted from the food source (called a food-derived bioactive technology) and reintroduced into consumer-friendly lifestyle products which are proven to maintain health (a functional food). Therefore, instead of eating four large servings of broccoli per week, the same benefit may be technically delivered via a 250ml orange juice drink containing the bioactive if consumed once per week.

How is Provexis differentiated from other companies in the market?
Provexis is an evidence-based business which means that we only develop food-derived bioactive technologies and functional food products that have been scientifically proven to deliver a health benefit. This is a different approach from those that promote functional food products in a more generic way with less scientific evidence. We believe that functional food products with strong scientific proof carrying health claims and endorsements will endure and prosper as this rapidly growing market matures.

Provexis is also differentiated with regard to our speed-to-market credentials and the fact that we can create shareholder value via a combination of technology licensing and own brand development.

What food-derived bioactive technologies are being developed by Provexis?
Provexis has developed Fruitflow, a patented extract from tomato that has been proven to inhibit blood platelet aggregation, thereby reducing the risk of thrombosis. A thrombosis is an aberrant blood clot that can lead to heart attack and stroke. Provexis has integrated Fruitflow into a fruit juice beverage called Sirco. When launched - initially in the United Kingdom - it will be the first functional food carrying the claim Helps maintain a healthy heart and benefit circulation with a measurable benefit within hours of consumption.

Provexis is developing a proprietary extract from a special breed of broccoli (non-GMO) which is enriched in compounds known to reduce the risk of specific cancers. Provexis intends to use this food-derived bioactive to underpin a new range of functional beverages with scientifically proven protective properties.

In addition, Provexis is developing a patented extract from plantain with a view to developing a novel medical food for the dietary management of Inflammatory Bowel Disease, specifically Crohns Disease in the first instance.

So the reaction to the Prelims is a fall in sp. This despite a positive chairman's statement. Note in particular (last para.) the 'confidence in securing the first (licenseing agreement) in the short-term... Suspect that the short-termers are out with their small profits. How short is short-term? Three months? News at AGM if not before? The point about a licensing deal is that it will be more or less gross equals nett and should certainly be very significant in terms of the current market cap. Good time to buy / top up.

Eric

with thanks to Phylis Stein over on iii

shows some good signs for the improving penetration of the company...



Hi Stephen

I know you are busy but I would like to pass on some (negative) feedback I have picked up regarding the H&B launch. It may be an isolated instance but if not, then there is some work needed to be done to rectify the situation - and I hope you are already on the case.

The following came from a regular (if somewhat cynical) poster on the iii.co.uk bulletin board:
"I had a chat with the H&B manager who told me that it (Sirco one shot) had come in 'last Tuesday', totally unexpected, no warning, no marketing material with it, and no explanation of what it is or what it does or who its aimed at etc... The manager had never heard of it so was totally uninterested. She did explain that new lines normally come with full details of the product, its benefits etc and marketing material. So thats going to fly off the shelves, isnt it?"

The same poster also pointed this out: "Has anyone called Tesco to check the latest number of their stores actively stocking Sirco? Remember it was only 301 a few weeks ago, not the 550 claimed by PXS."

Now, I fully understand that you cannot even attempt to correct misinformation and misunderstandings on the part of every commentator, but I would like to point out that the share price is very important and not just to investors. If you consider the share drawdown arrangement then clearly every penny on the price is of major consequence when it comes to PXS needing to raise cash. Better communication with the broader market can only help and a steady stream of positive news is really the best way. Meanwhile, if you can shed some light on the above comments I would be grateful. As ever, I recognise the scale of the task of launching a new product but hope you can provide some re-assurance on this.
Many thanks
****

14 July 2006 20:33:08
Stephen Moon (stephen@stephenmoon.com)

Hi Will

Apologies for the delay in replying, I have had a day holiday, so switched the phone off for a while.

Regarding H&B we have provided their head office with a bespoke marketing package including a custom poster advert. The implementation in H&B can sometimes be a bit slower than a major multiple, but it does come right. We have an agent who will call on all the stores on a regular four week cycle, and that is underway. We have gone with a Tetrapak package, as not all health stores have coolers, and therefore this pack will give us the best long term distribution potential, especially as the aseptic format gives us 9 months's shelf-life.

As well as H&B we are starting to move into independents, and had signed five large wholesalers as of Monday last. Regarding Tesco, I can't remember if I have replied to you on this, as there have been a number of emails on the subject. The situation is crystal clear: I personally look at EPOS data collected over the till of every Tesco store every Wednesday - I can see every bar code swiped for every single pack of Sirco in every Tesco store by day. As well as Sirco, I look at all our competitors weekly. I can tell you categorically that last week we sold Sirco in 514 Tesco stores -this number has been consistent for a number of weeks. I was concerned that we had lost two strongly performing stores, so we immediately sent in merchandising staff to investigate and rectify - we are very focused on this important account. The discrepancy between 514 and the quoted 550 is because stores in Northern Ireland and some of the Scottish areas are difficult to manage within the Tesco system, but we are still pushing there.

I hope this allays some of your concern.

Best regards
Stephen

****

typical!!! i was stopped out last week . now this ......

PROVEXIS PLC

('Provexis' or the 'Company')

Exclusivity Agreement


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has entered into an exclusivity
agreement for a period of 12 months with a major global branded food business
('Partner'), who, for reasons of confidentiality, cannot be named, for the joint
development and use of its patented Fruitflow(TM)heart-health technology.
Fruitflow(TM)is a bioactive food ingredient that reduces blood platelet
aggregation, a significant contributing factor to thrombosis, which can cause
heart attack or stroke.

Under the terms of the agreement, Provexis and its Partner will develop a
second-generation concentrated format of the Fruitflow(TM)product. The new
format will increase its applicability across all food, beverage, supplement and
medical formats. During the 12 month exclusivity period, the companies intend to
ensure technical and economic targets for the new format are met, and to
negotiate a global licence and supply arrangement for the FruitflowTM
technology.

According to Leatherhead Food International the market for heart benefit foods
is worth $4bn globally.

The scope of the exclusivity agreement covers all food and beverage formats
globally, with some specific exemptions. Provexis retains the right to
commercialise the Fruitflow(TM)technology on a global basis in the areas of
fruit juice and juice drinks, products marketed for deep vein thrombosis (DVT),
dietary supplements and prescribed medical products.
Commenting on the signing of the exclusivity agreement, Dawson Buck, Chairman of
Provexis said:

'This is an important milestone for Provexis. This agreement with a major global
brand owner will accelerate the development of our second generation
Fruitflow(TM) technology. If all goes well, we expect to move to a long-term,
global licensing deal with our partner within 12 months. In addition, we will
have a new technology platform to facilitate entry into the substantial consumer
and medical categories that fall outside of the agreement, and to this end, we
continue discussions with further potential licence partners.'

and this .....

Provexis plc, the nutraceutical company that develops scientifically-proven
functional and medical foods, today announces that Dr Stephen Franklin is
stepping down with immediate effect from his role as Chief Executive Officer,
and will not be seeking re-election to the Board at the Company's forthcoming
Annual General Meeting. Dr Franklin will continue to work with the Company until
early 2007 as Acting Director of Research. In this capacity he will complement
the Company's research and development team progressing late phase development
of the Company's proprietary technologies. The Company announces that Stephen
Moon has been appointed as Chief Executive Officer with immediate effect.
Stephen Moon, formerly Commercial Director of Provexis, has been with the
Company since February 2003.

Stephen Moon has been central to the strategic development of the Company. He
has been responsible for identifying and implementing revenue generating
opportunities, in particular pursuing key licensing agreements, and was
instrumental in the successful launch of the Company's Sirco(TM)product, which
incorporates its patented Fruitflow(TM)technology, into the major UK
supermarkets, Tesco and Waitrose, in February 2006. Prior to joining Provexis,
Stephen worked as Strategy Planning and Worldwide Business Development Director
at GlaxoSmithKline's nutritional healthcare division and in manufacturing and
supply chain roles at BP, Dalgety and Quaker.

Dawson Buck, Chairman of Provexis plc said:

'The Board would like to thank Dr Stephen Franklin for his significant
contribution to the establishment and development of the Company, particularly
since the reverse takeover of Nutrinnovator in June 2005. In addition we are
pleased that he will continue to work with the Company in an advisory capacity.

'I am delighted that Stephen Moon has accepted the role of Chief Executive. He
is highly regarded in the global nutritional sector and his wealth of experience
and extensive knowledge of the Company will prove invaluable in the next stage
of Provexis' development.

'As stated at the preliminary results announcement, the Board is pleased with
the progress that the Company has made since its admission to AIM in June 2005.
We believe that the Company is well-positioned to continue its growth by
capitalising on global opportunities with potential licensing partners in the
rapidly growing functional and medical foods market.'

Now doubled my shares had some that i bought at 12p,sold the rest for a small profit before the drop.Very good news today.

ah bollox!! i knew this would happen once i was out.

Provexis PLC
31 July 2006


PROVEXIS PLC
('Provexis')

Sirco Distribution Gains


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has extended the distribution of
its Sirco(TM) heart health juice drink, securing 235 Morrisons outlets with
effect from 14 August 2006.

Sirco(TM) contains the patented Fruitflow(TM) bioactive food ingredient that
reduces blood platelet aggregation, a significant contributing factor to
thrombosis, which can cause heart attack or stroke.

Sirco(TM) is currently distributed in approximately 640 Tesco and Waitrose
supermarkets, and also in 150 Holland & Barratt health food stores, as well as a
number of independent health food wholesalers.

Commenting on the new distribution, Stephen Moon, CEO of Provexis said:

'Securing this important retailer sees us continue to extend distribution of our
patented, scientifically-proven Sirco(TM) product in line with our business
plan.'

Time to take notice of PXS and those patient investors who have continued to have faith in the product development.

Unnamed collaboration of last six months or so is today announced as Unilever.

are you still in Bosley?